<sr class="rzcik"></sr>

华体会hth

Be the most trusted biotech company

2025-01-06

Henlius Receives the NMPA IND Approval for Its PD-L1-Targeting ADC HLX43 in Combination with Novel Anti-PD-1 mAb Serplulimab
2024-12-24

First Chinese Patient Dosed for Phase 3 MRCT on ER+/HER2- Breast Cancer of HLX78
2024-12-20

Latest Results of Serplulimab in The Field of Pancreatic Cancer Released In APA/JPS/CAP/IAP 2024 Annual Meeting in Oral Presentation
2024-12-19

Palleon Pharmaceuticals and Henlius Collaborate to Advance Glycan Editing as a Treatment for Autoimmune Diseases
2024-12-17

Henlius Becomes Newest Member of Biosimilars Forum
2024-12-16

Latest Results of Serplulimab in The Neoadjuvant Treatment of ESCC Released In 2024 ESMO IO
2024-12-09

Latest Results of 5 Clinical Trials Released at ESMO Asia 2024
2024-12-04

Henlius Receives IND Approval from NMPA for a Phase 1b/2 Clinical Trial of Its Novel PD-L1-Targeting ADC HLX43
2024-12-04

Henlius Receives Approval form NMPA for a Phase 2 Clinical Trial of Its Novel Anti-HER2 mAb HLX22

1
2
3
4
5
6
7
...
43